Patents Assigned to Rock Creek Pharmaceuticals, Inc.
-
Publication number: 20140206656Abstract: This disclosure provides products, including pharmaceutical compositions and dietary supplements, which are useful for anti-inflammatory support.Type: ApplicationFiled: January 29, 2014Publication date: July 24, 2014Applicant: Rock Creek Pharmaceuticals, Inc.Inventor: Jonnie R. Williams
-
Publication number: 20140057949Abstract: This disclosure provides beverage products comprising a compound of Formula I, such as anatabine, suitable for human consumption.Type: ApplicationFiled: October 31, 2013Publication date: February 27, 2014Applicant: Rock Creek Pharmaceuticals, Inc.Inventor: Jonnie R. Williams
-
Publication number: 20130298921Abstract: An alkaloid composition for an inhaler contains a solvent and at least about 25 wt. % anatabine based on the total alkaloid weight of the composition. The alkaloid composition may be contained in a refilling cartridge for an inhaler, or in a container as part of a kit for refilling an inhaler. The alkaloid compositions disclosed herein feature a balanced form of alkaloids to provide an attractive alternative to smoking tobacco, in which nicotine makes up about 90 wt. % of the total alkaloid content. The alkaloid compositions are characterized by a significant quantity of anatabine, which has lower toxicity than other alkaloids such as nicotine. The alkaloid compositions enable individuals to experience the pleasure-enhancing attributes of conventional cigarette smoking, while avoiding exposure to combusted materials and other potentially hazardous components present in tobacco.Type: ApplicationFiled: July 19, 2013Publication date: November 14, 2013Applicant: Rock Creek Pharmaceuticals, Inc.Inventor: Jonnie R. Williams
-
Patent number: 8557999Abstract: Anatabine citrate and formulations containing anatabine citrate are useful for promoting health and well-being.Type: GrantFiled: May 22, 2012Date of Patent: October 15, 2013Assignee: Rock Creek Pharmaceuticals, Inc.Inventors: Tom Thomas Puthiaparampil, Thomas Kanathkunn David, Muppala Sarveswara Raju
-
Publication number: 20130195780Abstract: A skin care product includes a compound of Formula I, IA, or IB (e.g., anatabine), or a salt thereof, and a suitable cosmetic or pharmaceutical vehicle. In some aspects, the skin care product is a paste, cream, lotion, gel, moisturizer, cleanser, or sunscreen. In some embodiments, the skin care product is applied topically to reduce inflammation, redness, and/or irritation, and/or to improve the appearance of the skin. In other embodiments, the skin care product is applied topically to treat an autoimmune and/or dermatological condition such as acne, psoriasis, and/or rosacea.Type: ApplicationFiled: March 14, 2013Publication date: August 1, 2013Applicant: ROCK CREEK PHARMACEUTICALS, INC.Inventor: Rock Creek Pharmaceuticals, Inc.
-
Publication number: 20130053355Abstract: This disclosure provides products, including pharmaceutical compositions and dietary supplements, which are useful for anti-inflammatory support.Type: ApplicationFiled: June 12, 2012Publication date: February 28, 2013Applicant: Rock Creek Pharmaceuticals, Inc.Inventor: Jonnie R. Williams
-
Publication number: 20120245202Abstract: Pharmaceutical compositions comprising an isolated form of a compound of Formula I or IA (e.g., anatabine or S-(?)-anatabine) or a salt thereof can be used to treat disorders comprising an inflammatory component, including chronic, low-level inflammation. Compounds of Formula I also can be provided, for example, in other vehicles such as beverage products and consumer products such as lotions and creams.Type: ApplicationFiled: September 19, 2011Publication date: September 27, 2012Applicant: ROCK CREEK PHARMACEUTICALS, INC.Inventor: Jonnie R. Williams
-
Publication number: 20120232115Abstract: Anatabine is obtained by reacting benzophenoneimine with 3-aminomethyl pyridine to form benzylhydrylidene-pyridin-3-yl-methyl-amine. The benzylhydrylidene-pyridin-3-yl-methyl-amine is treated with a non-nucleophilic base and a dielectrophile, such as cis-1,4-dichloro-2-butene, followed by acidification, then basification, to provide anatabine. The resulting anatabine is substantially free from contaminants and displays good stability. In an alternative embodiment, the benzylhydrylidene-pyridin-3-yl-methyl-amine may be used in the synthesis of other alkaloids such as anabasine, nornicotine, N-methylanabasine, and anabaseine.Type: ApplicationFiled: May 22, 2012Publication date: September 13, 2012Applicant: ROCK CREEK PHARMACEUTICALS, INC.Inventors: Tom Thomas Puthiaparampil, Thomas Kanathkunn David, Muppala Sarveswara Raju
-
Patent number: 8241680Abstract: Nutraceutical compositions containing anatabine and Yerba maté extract are efficacious for temporarily reducing the desire to smoke, reducing nicotine cravings, the treatment of smoking cessation, tobacco withdrawal symptoms, tobacco dependence, weight loss, and/or related disorders.Type: GrantFiled: June 30, 2010Date of Patent: August 14, 2012Assignee: Rock Creek Pharmaceuticals, Inc.Inventors: Jonnie R. Williams, Curtis Wright
-
Publication number: 20120196899Abstract: Pharmaceutical compositions comprising an isolated form of a compound of Formula IB (e.g., R-(+)-anatabine) or a salt thereof can be used to treat disorders comprising an inflammatory component, including chronic, low-level inflammation. Compounds of Formula I also can be provided, for example, in other vehicles such as beverage products and consumer products such as lotions and creams.Type: ApplicationFiled: September 19, 2011Publication date: August 2, 2012Applicant: Rock Creek Pharmaceuticals, Inc.Inventor: Jonnie R. Williams
-
Patent number: 8207346Abstract: Anatabine is obtained by reacting benzophenoneimine with 3-aminomethyl pyridine to form benzylhydrylidene-pyridin-3-yl-methyl-amine. The benzylhydrylidene-pyridin-3-yl-methyl-amine is treated with a non-nucleophilic base and a dielectrophile, such as cis-1,4-dichloro-2-butene, followed by acidification, then basification, to provide anatabine. The resulting anatabine is substantially free from contaminants and displays good stability. In an alternative embodiment, the benzylhydrylidene-pyridin-3-yl-methyl-amine may be used in the synthesis of other alkaloids such as anabasine, nornicotine, N-methylanabasine, and anabaseine.Type: GrantFiled: March 23, 2010Date of Patent: June 26, 2012Assignee: Rock Creek Pharmaceuticals, Inc.Inventors: Tom Thomas Puthiaparampil, Thomas Kanathkunn David, Muppala Sarveswara Raju
-
Publication number: 20120003341Abstract: Nutraceutical compositions containing anatabine and Yerba maté extract are efficacious for temporarily reducing the desire to smoke, reducing nicotine cravings, the treatment of smoking cessation, tobacco withdrawal symptoms, tobacco dependence, weight loss, and/or related disorders.Type: ApplicationFiled: June 30, 2010Publication date: January 5, 2012Applicant: Rock Creek Pharmaceuticals, Inc.Inventors: Jonnie R. Williams, Curtis Wright
-
Publication number: 20110237627Abstract: Anatabine is obtained by reacting benzophenoneimine with 3-aminomethyl pyridine to form benzylhydrylidene-pyridin-3-yl-methyl-amine. The benzylhydrylidene-pyridin-3-yl-methyl-amine is treated with a non-nucleophilic base and a dielectrophile, such as cis-1,4-dichloro-2-butene, followed by acidification, then basification, to provide anatabine. The resulting anatabine is substantially free from contaminants and displays good stability. In an alternative embodiment, the benzylhydrylidene-pyridin-3-yl-methyl-amine may be used in the synthesis of other alkaloids such as anabasine, nornicotine, N-methylanabasine, and anabaseine.Type: ApplicationFiled: March 23, 2010Publication date: September 29, 2011Applicant: ROCK CREEK PHARMACEUTICALS, INC.Inventors: Tom Thomas Puthiaparampil, Thomas Kanathkunn David, Muppala Sarveswara Raju
-
Publication number: 20110151035Abstract: A smoking cessation aid is in the form of a lozenge containing powdered tobacco and a therapeutically effective amount of a silver salt. In another embodiment, a lozenge contains nicotine and a therapeutically effective amount of a silver salt. In yet another embodiment, a lozenge contains (i) at least one of anatabine, anabasine, and nornicotine, and (ii) a therapeutically effective amount of a silver salt.Type: ApplicationFiled: December 13, 2010Publication date: June 23, 2011Applicant: ROCK CREEK PHARMACEUTICALS, INC.Inventor: Curtis Wright, IV
-
Patent number: D639178Type: GrantFiled: August 3, 2010Date of Patent: June 7, 2011Assignee: Rock Creek Pharmaceuticals, Inc.Inventors: Jonnie Williams, Jr., Friedrich G. Geck, Pam Krausman